<DOC>
	<DOCNO>NCT01045434</DOCNO>
	<brief_summary>An open label , balance , randomize , two-treatment , two-period , two-sequence , single dose , crossover oral bioequivalence study Omeprazole Magnesium 20 mg DR capsule Dr. Reddy 's Laboratories Limited , India Prilosec OTCTM 20 mg ( Omeprazole Magnesium DR Tablets ) Procter Gamble , Cincinnati , Sweden 38 healthy , adult , human subject feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Omeprazole Magnesium 20 mg DR Capsule Under Fed Conditions</brief_title>
	<detailed_description>This study use crossover design consist 2 treatment , 2 sequence 2 period . Study Period-I IT separate washout period 14 day . Use crossover design appropriate since enables comparison treatment within subject use intrasubject variability thus improve precision treatment comparison . Also use 14 day washout period successive drug administration eliminate chance residual drug present precede period ( i.e Period 1 ) next period ( i.e Period II ) .</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Healthy human subject within age range 18 45 year . Nonsmokers since least six month . Willingness provide write informed consent participate study . Bodymass index ≥18.5 kg/m2 and≤ 24.9 kglm2 , body weight less 50 kg . Absence significant disease clinically significant abnormal laboratory value laboratory evaluation , medical history physical examination screen . Normal 12lead ECG one abnormality consider clinically insignificant . Normal chest Xray PA view . Comprehension nature purpose study compliance requirement protocol . Female Subjects : child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence , postmenopausal least 1 year , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject . Personal/family history allergy hypersensitivity Omeprazole ally drug . Past history anaphylaxis angioedema . Any major illness past three month clinically significant ongoing chronic medical illness .e.g . congestive heart failure , hepatitis , pancreatitis etc . Presence clinically significant abnormal value screen e.g . significant abnormality Liver Function Test ( LFT ) , Renal ( kidney ) Function Test ( RFT ) , etc . Any cardiac , renal liver impairment , organ system impairment . History seizure psychiatric disorder . Presence disease marker HIV 1 2 , hepatitis B C virus Consumption alcohol two year , consumption three alcoholic drink per day consumption alcohol within 48 hour prior dose study [ one drink equal one unit alcohol [ one glass wine , half pint beer , one measure ( one ounce ) spirit ] . Consumption xanthine contain derivative ( coffee , tea , cola drink , chocolate ) within 48 hour checkin period . Use recreational drug history drug addiction . Participation clinical trial within past 3 month . Inaccessibility vein leave right arm . Donation blood ( one unit 350 mL ) within 3 month prior receive first dose study medication . Receipt prescription drug therapy within four week overthecounter ( OTC ) drug within two week prior receive first dose study medication repeat use drug within last four week . An unusual diet , whatever reason e.g . low sodium diet , two week prior receive medication subject 's participation study . Consumption grapefruitcontaining food beverage within 7 day prior receive first dose study medication period Recent history dehydration diarrhoea , vomit reason within period 24 hour prior study . Female volunteer demonstrate positive pregnancy screen currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>omeprazole</keyword>
	<keyword>crossover</keyword>
</DOC>